What is the best frontline therapy for patients with CLL and 17p deletion? (Q37820433)

23 August 2017

1 reference

title

What is the best frontline therapy for patients with CLL and 17p deletion? (English)

1 reference

23 August 2017

3

William G Wierda

1 reference

23 August 2017

2

Michael J Keating

1 reference

23 August 2017

1

Xavier C Badoux

1 reference

23 August 2017

publication date

1 March 2011

1 reference

Current hematologic malignancy reports

23 August 2017

published in

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

36-46

1 reference

Chemoimmunotherapy of chronic lymphocytic leukemia

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Localization of gene for human p53 tumour antigen to band 17p13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

p53: guardian of the genome and policeman of the oncogenes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Risk stratification in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

p14ARF links the tumour suppressors RB and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

21 January 2018

The mdm2 proto-oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Mdm2-mediated ubiquitylation: p53 and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

The p53 pathway: positive and negative feedback loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Cytogenetic Findings and Survival in B-cell Chronic Lymphocytic Leukemia. Second IWCCLL Compilation of Data on 662 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

TP53 mutation and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Allotransplantation for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Flavopiridol in chronic lymphocytic leukemia: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-010-0069-3

Chlorambucil in chronic lymphocytic leukemia: mechanism of action

21 January 2018

1 reference

12 December 2020

In vivo 'Purging' of residual disease in CLL with Campath-1H

1 reference

12 December 2020

Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis

1 reference

12 December 2020

Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo

1 reference

12 December 2020

Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance.

1 reference

12 December 2020

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

1 reference

12 December 2020

Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia

1 reference

12 December 2020

In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients

1 reference

12 December 2020

The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53

1 reference

12 December 2020

Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.

1 reference

12 December 2020

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

1 reference

12 December 2020

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis

1 reference

12 December 2020

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

1 reference

12 December 2020

The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin

1 reference

12 December 2020

P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia

1 reference

12 December 2020

10.1007/S11899-010-0069-3

Identifiers

DOI

1 reference

23 August 2017

1 reference